Leerink keeps an Outperform rating on MacroGenics (MGNX) with an $8 price target following the Q3 report. The company recently announced it had sold global rights of Margenza to TerSera Therapeutics for $40M upfront and up to $35M in aggregate sales milestones, the analyst tells investors in a research note. The firm views the deal positively, saying it provides non-dilutive financing and will allow MacroGenics to focus on its pipeline efforts.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MGNX: